Article

BCG failure leads to heightened risk of bladder cancer death

Chicago-Patients with carcinoma in situ or recurrent Ta, Tis, or T1 bladdercancer are at increased risk of dying of the disease within 5 years unlessthey achieve a complete response with bacille Calmette-Guérin therapy,say researchers from the Southwest Oncology Group.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.